THE FIRST AND ONLY DIABETIC DES RANDOMIZED TRIAL DESIGNED FOR SUPERIORITY: DIAB8

WE ARE ALVIMEDICA

WORLD LEADING QUALITY

LIVING INNOVATION

BETTER OUTCOMES FOR PATIENTS

Alvimedica, officially unveiled the details of the Diab8 study, the first diabetic Drug-Eluting Stent (DES) randomized trial, during the Annual Meeting of EuroPCR 2018.
News

A global manufacturer of unique interventional medical devices, harnessing the power of innovation to improve our patient’s quality of life. We tackle today’s toughest patients clinical conditions by creating innovative products.
About

We create the highest quality products, trusted by leading professionals around the world.
About

Our driving passion is to improve the quality of life through innovative technology, creating a better future by investing in both clinical research and product development.
Products

Alvimedica is committed to improving patient outcomes, as well as tackling global issues such as Diabetes, which we are 100% committed to defeating.
Products

PRODUCTS

DIABETES

WORKING FOR
DIABETES
PROJECTS

Diabetes is a number of diseases that involve
problems with hormone insulin.
Normally...

NEWS

ReCre8: A randomized trial evaluating a polymer-free coronary drug-eluting stent in an all-comers patient population

ReCre8: A randomized trial evaluating a polymer-free coronary drug-eluting stent in an all-comers patient population

Diab8: The randomized clinical trial comparing the polymer-free Amphilimus™ eluting stent to the Everolimus eluting stent in all-comer Diabetes Mellitus patients

Diab8: The randomized clinical trial comparing the polymer-free Amphilimus™ eluting stent to the Everolimus eluting stent in all-comer Diabetes Mellitus patients

The First and Only Diabetic DES Randomized Trial Designed for Superiority: DIAB8

Alvimedica, officially unveiled the details of the Diab8 study, the first diabetic Drug-Eluting Stent (DES) randomized trial, during the Annual Meeting of EuroPCR 2018

DISCOVER